Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,944 shares of the company’s stock after selling 6,046 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Neurocrine Biosciences were worth $4,948,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth $3,662,000. XTX Topco Ltd lifted its holdings in shares of Neurocrine Biosciences by 159.2% during the third quarter. XTX Topco Ltd now owns 8,665 shares of the company’s stock valued at $998,000 after purchasing an additional 5,322 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Neurocrine Biosciences by 83.3% in the 3rd quarter. National Bank of Canada FI now owns 1,351 shares of the company’s stock valued at $156,000 after purchasing an additional 614 shares during the period. iA Global Asset Management Inc. purchased a new position in Neurocrine Biosciences in the 3rd quarter worth about $306,000. Finally, EP Wealth Advisors LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth about $483,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 0.1 %

Neurocrine Biosciences stock opened at $126.70 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The firm’s fifty day simple moving average is $121.75 and its 200-day simple moving average is $130.62. The company has a market capitalization of $12.83 billion, a P/E ratio of 33.97 and a beta of 0.34.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 1st. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $165.18.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.